DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Manufacturer of Controlled Substances Registration: Boehringer Ingelheim Chemical, Inc.

ACTION: Notice of registration.

SUMMARY: Boehringer Ingelheim Chemical, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The DEA grants Boehringer Ingelheim Chemical, Inc. registration as a manufacturer of the controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated May 28, 2014, and published in the **Federal Register** on June 4, 2014, 79 FR 32321, Boehringer Ingelheim Chemical, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805–9372, applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemical, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances:

Controlled substance	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Methadone (9250)	II
Methadone Intermediate (9254)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. In reference to methadone intermediate (9254) the company plans to produce methadone HCL active pharmaceutical ingredients (APIs) for sale to its customers.

Dated: January 9, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2015–01289 Filed 1–23–15; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Manufacturer of Controlled Substances Registration: S & B Pharma, Inc.

ACTION: Notice of registration.

SUMMARY: S & B Pharma, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The DEA grants S & B Pharma, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated July 1, 2014, and published in the **Federal Register** on July 8, 2014, 79 FR 38564, S & B Pharma, Inc., DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 91702–3232 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of S & B Pharma, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

Controlled Substance	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Tetrahydrocannabinols (7370)	I
Methamphetamine (1105)	II
Pentobarbital (2270)	II
Nabilone (7379)	II
4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333).	II
Tapentadol (9780)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers.

Dated: January 9, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2015–01287 Filed 1–23–15; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Manufacturer of Controlled Substances Registration: Research Triangle Institute

ACTION: Notice of registration.

SUMMARY: Research Triangle Institute applied to be registered as a manufacturer of certain basic classes of controlled substances. The DEA grants Research Triangle Institute registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated July 2, 2014, and published in the **Federal Register** on July 14, 2014, 79 FR 40781, Research Triangle Institute, Kenneth S. Rehder, Ph.D., Hermann Building East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Research Triangle Institute to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

Controlled substance	Schedule
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
Cocaine (9041)	II

The company will manufacture marihuana and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse.

Dated: January 9, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2015–01301 Filed 1–23–15; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Manufacturer of Controlled Substances Registration: Noramco, Inc.

ACTION: Notice of registration.

SUMMARY: Noramco, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The DEA grants Noramco, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION:

By notice dated January 14, 2014, and published in the **Federal Register** on January 22, 2014, 79 FR 3627, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted to this notice. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed:

Controlled substance	Schedule
Codeine-N-oxide (9053)	I
I=≥01≥≤Dihydromorphine (9145)	I
Morphine-N-oxide (9307)	I
Amphetamine (1100)	II
Methylphenidate (1724)	II
Phenylacetone (8501)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Opium extracts (9610)	II
Opium fluid extract (9620)	II
Opium tincture (9630)	II
Opium, powdered (9639)	II
Opium, granulated (9640)	II
Oxymorphone (9652)	II
Noroxymorphone (9668)	II
Tapentadol (9780)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Dated: January 9, 2015.

Joseph T. Rannazzisi,

Deputy Assistant Administrator.

[FR Doc. 2015–01303 Filed 1–23–15; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Office of Justice Programs

[OJP (NIJ) Docket No. 1680]

Offender Tracking Systems Market Survey

AGENCY: National Institute of Justice, DOJ.

ACTION: Notice of Request for Information.

SUMMARY: The National Institute of Justice (NIJ) is soliciting information in relation to the upcoming National Criminal Justice Research, Test, and Evaluation Center (NIJ RT&E Center) ''Market Survey of Location-based Offender Tracking Technologies.'' This market survey will be published by NIJ to assist prospective agencies in their assessment of relevant information on commercially available offender tracking systems (OTS) marketed for use by the criminal justice community, prior to making purchasing decisions. The NIJ RT&E Center invites comments with regard to the market survey, including which categories of information are appropriate for comparison. Vendors of such technology are also invited to provide promotional material (*e.g.,* slick sheet) and images of the technology (*e.g.,* a print-quality photograph).

DATES: Responses to this request will be accepted through 11:59 p.m. Eastern Time on February 25, 2015.

ADDRESSES: Responses to this request may be submitted electronically in the body of or as an attachment to an email sent to *administrator@nijrtecenter.org* with the recommended subject line ''OTS Federal Register Response''. Questions and responses may also be sent by mail (please allow additional time for processing) to the address: National Criminal Justice Research, Test and Evaluation Center, ATTN: OTS Federal Register Response, Johns Hopkins University Applied Physics Laboratory, 11100 Johns Hopkins Road, Mail Stop 17N444, Laurel, MD 20723–6099.

FOR FURTHER INFORMATION CONTACT: For more information on this request for information contact Steven Taylor (NIJ RT&E Center) at (443) 778–9348 or *administrator@nijrtecenter.org.* For more information on the NIJ RT&E Center, visit *http://nij.gov/funding/awards/Pages/award-detail.aspx?award=2013-MU-CX-K111* and view the description or contact Jack Harne, by telephone at 202–616–2911 or by email at *Jack.Harne@usdoj.gov*. Please note that these are not toll-free telephone numbers.

SUPPLEMENTARY INFORMATION:

Information Sought: The NIJ RT&E Center seeks input to its upcoming ''Market Survey of Location-based Offender Tracking Technologies.'' This technology, consisting of hardware and software component, is designed to determine and report at programmed intervals the geographic location at a particular time of an individual who is subject to criminal justice system supervision. Whether an agency faces a mandate to track domestic violence or sex offenders, has a need to more closely monitor higher risk offenders, or is looking for confinement alternatives for low-risk offenders, this technology can often be a practical tool for supervising and managing select individuals.

This market survey will be published by NIJ to assist prospective agencies in their assessment of relevant information on commercially available OTS marketed for use by the criminal justice community, prior to making purchasing decisions. Vendors who respond to this